Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34+hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma: Mobilization with Plerixafor + G-CSF in Elderly NHL and MM Patients